Table 1 The tumor sample distribution of the 649 microarrays with corresponding controls among the tumor classes and tumor entities used in our analysis
From: The functional cancer map: A systems-level synopsis of genetic deregulation in cancer
Tumor class | Tumor entity | Analyzed Controls | Number of Samples |
|---|---|---|---|
Blood | Acute Lymphoblastic Leukemia Peripheral Blood, Grade Pre-B | Stratagene | 9 |
Bone marrow | Acute Lymphoblastic Leukemia Bone Marrow, Grade Common | Stratagene | 35 |
Bone marrow | Acute Lymphoblastic Leukemia Bone Marrow, Grade Pre-B | Stratagene | 33 |
Bone | Extraskeletal Myxoid Chondrosarcoma | CRH | 10 |
Breast | Breast Carcinoma | Stratagene | 94 |
Breast | Breast Carcinoma Invasive Ductal Carcinoma, Grade 2 | Stratagene | 31 |
Breast | Breast Carcinoma Invasive Ductal Carcinoma, Grade 3 | Stratagene | 19 |
Breast | Breast Carcinoma Invasive Lobular Carcinoma, Grade 2 | Stratagene | 19 |
Liver | Human Hepatocellular Carcinoma | Stratagene | 19 |
Lymhpocytes | Follicular Lymphoma | CRG | 24 |
Mixture | Solitary Fibrous Tumor | CRG | 7 |
Muscle | Leiomyosarcoma | CRG | 7 |
Ovarian | Ovarian Carcinoma | CRD | 39 |
Pancreas | Adenocarcinoma, Pancreas | CRH | 10 |
Pancreas | Adenocarcinoma, Pancreas, Grade II | CRH | 5 |
Pancreas | Adenocarcinoma, Pancreas, Grade III | CRH | 6 |
Prostate | Prostate Tumor, Grade T2b | Stratagene | 23 |
Prostate | Prostate Tumor, Grade T3a | Stratagene | 19 |
Prostate | Prostate Tumor, Grade T3b | Stratagene | 9 |
Renal | Conventional Renal Cell Carcinoma, Grade 1 | Stratagene | 9 |
Renal | Conventional Renal Cell Carcinoma, Grade 2 | Stratagene | 34 |
Renal | Conventional Renal Cell Carcinoma, Grade 3 | Stratagene | 94 |
Renal | Conventional Renal Cell Carcinoma, Grade 4 | Stratagene | 40 |
Skin | Dermatofibrosarcoma Protuberans | CRG | 6 |
Soft Tissue | Synovial Sarcoma | CRG | 5 |
Stomach | Stomach Cancer Before Treatment | CRF | 14 |
Stomach | Stomach Cancer, Placebo After 1 Year | CRF | 13 |
Testis | Testis Seminoma | CRG | 16 |